#For patients
Written for adults considering a peptide as part of their health management.
Orforglipron vs oral semaglutide in T2D
ACHIEVE-3 put the orforglipron pill head to head with the oral semaglutide pill in type 2 diabetes. Orforglipron won on HbA1c and lost on tolerability.
Semaglutide access and health inequity
Semaglutide works. Access does not follow need. Here is what fill-rate, pricing and policy data show about who actually gets treated, and who does not.
Semaglutide and wet AMD: signal vs proof
A 2026 study flagged semaglutide among five drugs with raised wet AMD reporting. Here is what that kind of signal can and cannot tell you.
What is food noise? Five theories
A 2026 Appetite review says food noise still has no settled definition. Here are the five theories behind it, and what the GLP-1 survey data shows.
BPC-157 for a running injury: evidence
A runner's forum question reflects real interest in BPC-157, but animal studies and anecdotes do not establish safe or effective injury treatment.
Retatrutide and gut-health claims
A podcast discussion can raise useful questions, but phase 2 retatrutide evidence does not make it an approved general tool for gut health.
STEP UP semaglutide muscle findings
A small STEP UP MRI subgroup found lower thigh fat infiltration and lower measured muscle volume, with sit-to-stand repetitions preserved.
What 49 Online GLP-1 Prescribers Required
A secret-shopper study found rapid access to GLP-1 prescriptions across 49 US websites, often without direct clinician-patient communication.
Tirzepatide, GLP-1 Drugs, and Gum Disease
A large propensity-matched study links tirzepatide to lower periodontal disease risk than other GLP-1 drugs in type 2 diabetes.
MASLD Screening Without a Liver Biopsy
A new review explains how FIB-4 screens for MASLD and MASH in primary care, now that semaglutide and resmetirom can treat confirmed cases.
What Patients Want in an Obesity Drug
A US survey of 800 adults finds route of administration and weight-loss efficacy outweigh simpler dosing rules when picking an obesity medication.
Ozempic Face: What the Research Says
Researchers reviewed 23 resources on GLP-1 drugs and facial volume loss. A peer response says the evidence for a distinct semaglutide effect is weak.